Cargando…

Patient reported toxicity and quality of life after hypofractionated high-dose intensity-modulated radiotherapy for intermediate- and high risk prostate cancer

BACKGROUND AND PURPOSE: For irradiation of localized prostate-cancer, moderately-hypofractionated regimens with a variety of dose per fraction are used. We adopted a regimen of 70 Gy in 28 fractions of 2.5 Gy, using state of the art radiotherapy (RT) and closely monitored the efficacy, toxicity and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Houben, Jeroen, McColl, Gill, HAM Kaanders, Johannes, Smeenk, Robert J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170415/ https://www.ncbi.nlm.nih.gov/pubmed/34113724 http://dx.doi.org/10.1016/j.ctro.2021.05.005

Ejemplares similares

Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity
por: Thomson, David, et al.
Publicado: (2012)

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer
por: Anwar, Mekhail, et al.
Publicado: (2016)

Comparative evaluation of hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate and high risk prostate cancer
por: Soni, Abhishek, et al.
Publicado: (2022)

Cost-effectiveness analysis of ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy for intermediate- to high-risk localized prostate cancer
por: He, Jiaoxue, et al.
Publicado: (2023)

High-dose hypofractionated X-ray radiotherapy for hepatocellular carcinoma: Tumor responses and toxicities
por: HUANG, BING-SHEN, et al.
Publicado: (2013)

Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
por: Kim, Hun Jung, et al.
Publicado: (2016)

Hypofractionated Radiotherapy in Intermediate-Risk Prostate Cancer Patients: Long-Term Results
por: Valeriani, Maurizio, et al.
Publicado: (2022)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

Hypofractionated Radiotherapy in Localized, Low–Intermediate-Risk Prostate Cancer: Current and Future Prospectives
por: Lo Greco, Maria Chiara, et al.
Publicado: (2023)

Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials
por: Guo, Wei, et al.
Publicado: (2019)

Comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms
por: Tamihardja, Jörg, et al.
Publicado: (2021)

A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer
por: Murray, Julia, et al.
Publicado: (2020)

Review of Hypofractionated Radiotherapy for Prostate Cancer
por: Spyropoulou, Despina, et al.
Publicado: (2012)

The Role of Hypofractionated Radiotherapy in Prostate Cancer
por: Benjamin, Linus C., et al.
Publicado: (2017)

Ten Year Results of Extensive Nodal Radiotherapy and Moderately Hypofractionated Simultaneous Integrated Boost in Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer
por: Di Muzio, Nadia Gisella, et al.
Publicado: (2021)

Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis
por: Di Franco, Rossella, et al.
Publicado: (2017)

5-Years Analysis of Effectivity and Toxicity of Ultra-Hypofractionated Proton Radiotherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer—A Retrospective Analysis
por: Kubeš, Jiri, et al.
Publicado: (2023)

Long-Term Outcomes of Dose-Escalated Hypofractionated Radiotherapy in Localized Prostate Cancer
por: Lazo, Antonio, et al.
Publicado: (2022)

Prostate-specific antigen kinetics in hypofractionated radiation therapy alone for intermediate- and high-risk localized prostate cancer
por: Lee, Tae Hoon, et al.
Publicado: (2023)

Hypofractionated External-Beam Radiotherapy for Prostate Cancer
por: Cho, L. Chinsoo, et al.
Publicado: (2013)

Image guided intensity modulated hypofractionated radiotherapy in high-risk prostate cancer patients treated four or five times per week: analysis of toxicity and preliminary results
por: Valeriani, Maurizio, et al.
Publicado: (2014)

Hypofractionated intensity-modulated radiotherapy in patients with localized prostate cancer: a preliminary study
por: Kang, Hye Jin, et al.
Publicado: (2016)

Local Dose Effects for Late Gastrointestinal Toxicity After Hypofractionated and Conventionally Fractionated Modern Radiotherapy for Prostate Cancer in the HYPRO Trial
por: Heemsbergen, Wilma D., et al.
Publicado: (2020)

Image Guided Hypofractionated Radiotherapy by Helical Tomotherapy for Prostate Carcinoma: Toxicity and Impact on Nadir PSA
por: Barra, Salvina, et al.
Publicado: (2014)

SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer: Toxicity and quality of life assessment
por: Rucinska, Monika, et al.
Publicado: (2016)

Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis
por: Tamihardja, Jörg, et al.
Publicado: (2020)

Quantitative MRI Changes During Weekly Ultra-Hypofractionated Prostate Cancer Radiotherapy With Integrated Boost
por: van Schie, Marcel A., et al.
Publicado: (2019)

Equivalent normalized total dose estimates in cyberknife radiotherapy dose delivery in prostate cancer hypofractionation regimens
por: Sudahar, H., et al.
Publicado: (2012)

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
por: Dearnaley, David, et al.
Publicado: (2016)

Automated prediction of dosimetric eligibility for hypofractionated prostate radiotherapy
por: Lausch, Anthony, et al.
Publicado: (2017)

Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression
por: Kil, Whoon Jong, et al.
Publicado: (2013)

Intrafraction Prostate Motion Management for Ultra-Hypofractionated Radiotherapy of Prostate Cancer
por: Oehler, Christoph, et al.
Publicado: (2022)

Dose evaluation of inter- and intra-fraction prostate motion in extremely hypofractionated intensity-modulated proton therapy for prostate cancer
por: Feng, Sen-Quan, et al.
Publicado: (2023)

Dose–Response of TLD-100 in the Dose Range Useful for Hypofractionated Radiotherapy
por: Liuzzi, Raffaele, et al.
Publicado: (2020)

Predictive biomarkers of resistance to hypofractionated radiotherapy in high grade glioma
por: Biau, Julian, et al.
Publicado: (2017)

Evolution of Hypofractionated Accelerated Radiotherapy for Prostate Cancer – The Sunnybrook Experience
por: Musunuru, Hima Bindu, et al.
Publicado: (2014)

Hypofractionated Postoperative Radiotherapy for Prostate Cancer: Is the Field Ready Yet?
por: Mahase, Sean, et al.
Publicado: (2020)

Practical Guidelines on Implementing Hypofractionated Radiotherapy for Prostate Cancer in Africa
por: Swanson, William, et al.
Publicado: (2021)

Hypofractionation Adoption in Prostate Cancer Radiotherapy: Results of an International Survey
por: Sabbagh, Ali, et al.
Publicado: (2023)

Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy
por: Bracci, Stefano, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6p31js7836pgr2ark4lmh57ode